Cutaneous pseudolymphoma caused by tumor necrosis factor-α inhibitors was not induced by ustekinumab.
Shinichi
S
Imafuku
Ryoko
R
Tatsukawa
Kotaro
K
Ito
Juichiro
J
Nakayama
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D019310:Pseudolymphoma / Q000139:chemically induced*; D011565:Psoriasis / Q000188:drug therapy*; D012871:Skin Diseases / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000069549:Ustekinumab
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab